ER&D downshifts on weak Q4, gloomy 2025; more downgrades loom
Brokerages also felt that the pharma companies will aim to pass on the tariff hike to payors
Companies such as Sun Pharma which have a significant specialty portfolio could be less impacted than Indian peers in the US market given lower competition in niche segments
The key concern weighing on the stock is increased competitive intensity with the relaunch of Campa Cola by Reliance Consumer Products (RCPL) in March 2023
They get growth Rx from outsourcing, with fewer Trump tariff side effects
Realty index in the rearview as office demand pulls Reits out of a two-year slump
The Street believes that the correction is overdone and that the company has multiple growth opportunities in India and the African market
Investor firepower reloaded, targeting domestic growth, exports, and European rearmament
The sell-off has been across the board with 185 or 92.5 per cent of all Nifty 200 stocks witnessing a price decline and 68.5 per cent (137 of 200) falling 15 per cent or more during this period
The recent trigger for the stock is the acquisition of US-based Checkpoint Therapeutics
DEMAND BOILS OVER, PRICE HIKES SIZZLE: Room air conditioner majors eye scorching double-digit growth
Growth in consolidated sales at Rs 4,305 crore were led by the ethnic and direct to consumer business which were up 7-26 per cent
At close, Hindustan Petroleum Corporation (HPCL) was up 3.66 per cent, Bharat Petroleum Corporation (BPCL) was up 3.6 per cent and Indian Oil Corporation (IOC) was up 2.4 per cent
The company reported a 14 per cent Y-o-Y increase in revenues aided for growth across the key verticals
Thin-soled growth: Relaxo struggles to stay on its feet as footwear stocks lose their stride
IT services firms, while reporting modest single-digit revenue growth, saw improved margins. Here is the top 10 sectors' earnings scorecard
Shares of PVR Inox hit a 46-month low of Rs 968, falling 3 per cent on the BSE in Tuesday's intra-day trade in an otherwise firm market
GSK Pharma share price: The company's consolidated net profit jumped multifold to Rs 230 crore as compared to Rs 46 crore a year ago in the December quarter
GLOSS OVER: No fresh coat of optimism from brokerages as demand stays patchy
Balkrishna's current valuation at 14 times FY27 enterprise value to operating profit is attractive given a strong return on invested capital of 25 per cent in FY26